MedPath

Effect of Jyotishmati capsule in the management of Chittodvega Generalized Anxiety Disorder

Phase 3
Conditions
Health Condition 1: F411- Generalized anxiety disorder
Registration Number
CTRI/2023/09/057687
Lead Sponsor
Reeya Gamne
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients willing to take part in research study and ready to give written informed consent.

2.Patients will be selected according to DSM-V, ICD-10 criteria for anxiety disorders.

3.A score of less than 24on HAM-A scale.

4.Age group of 20 to 50 years of either sex.

5.Free of psychiatric conditions other than anxiety.

Exclusion Criteria

1.Current primary diagnosis of a comorbid disorder deemed to require treatment prior to GAD, such as major depressive disorder, panic disorder, social phobia, obsessive compulsive disorder, post-traumatic stress disorder, or drug dependency.

2.Currently undertaking CBT with a psychologist condition.

3.GAD (Chittodvega) due to drug abuse, a medication and due to general medical state like Hyperthyroidism

4.Alcoholic, and Self-harm or suicide risk

5.Diagnosed with psychosis, schizophrenia, or bipolar illness currently or in the past

6.Treatment with sertraline for two or more weeks within the previous three months

7.Pregnant and lactating mothers.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath